Graffinity | A Business Unit of Santhera Therapeutics AG
HomeAbout usTechnologyBusinessMediaContactEventsDirections
> Overview > Partners > Fee-for-Service > Benefit
 
Business | Overview
 
  Technology Access Business
Graffinity offers numerous benefits to its customers on a straightforward fee-for-service basis with no downstream obligations. The client provides target material, Graffinity will perform the fingerprint and active compounds are designed based on a comprehensive SAR analysis. As a result of a 3-months project Graffinity delivers an agreed upon number of compounds to its clients for secondary assays.

Cooperations
Going forward, Graffinity is actively seeking to collaborate with leading pharmaceutical and biotechnology companies in order to realize the full potential of its drug discovery paradigm. The Company employs a flexible business model which allows it to tailor programs to the specific needs of each partner.

RAISE process delivers
• Window to novel, diverse chemistry
• Fragments and low affinity binders built the basis for novelty
• Novel binding modes can be characterized early
• Fastest read on drug-ability of targets
• Earliest look at SAR that is technically possible
• Scalable technology and process to any number of targets
  Search using keywords  
 
  Print this page Print
 
Target History
• Various metabolic enzymes
• Kinases
(full length, catalytic domains)
• Proteases
• Protein-protein interaction targets
• Esterases
• Nuclear hormone receptors
• RNA polymerases
• Total 60 targets successfully tested
since 2004.
 
 
 
Pictures | Impressions
Pictures from Graffinity
 
 
 
  Printer Print this page
 
Home | About Us | Technology | Business | Media | Contact | Events | Directions
Site Information
© 2004-2008 Graffinity
All rights reserved. | Top of page